References
- MannersTManaging eye conditions in general practiceBMJ19973158168179345194
- AbelsonMBLoefflerOConjunctival allergen challenge: models in the investigation of ocular allergyCurr Allergy Asthma Rep2003336336812791217
- BieloryLOcular allergy overviewImmunol Allergy Clin North Am20082812318282543
- WüthrichBBrignoliRCanevasciniMGerberMEpidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient managementSchweiz Med Wochenschr1998128139143 German.9522418
- PittADSmithAFLindsellLVoonLWRosePWBronAJEconomic and quality-of-life impact of seasonal allergic conjunctivitis in OxfordshireOphthalmic Epidemiol200411173314977494
- BlaissMSAllergic rhinoconjunctivitis: burden of diseaseAllergy Asthma Proc20072839339717883905
- NiederkornJYImmune regulatory mechanisms in allergic conjunctivitis: insights from mouse modelsCurr Opin Allergy Clin Immunol2008847247618769204
- LeibowitzHMThe red eyeN Engl J Med200034334535110922425
- Bepreve®. [Package insert]Irvine, CAISTA Pharmaceuticals Inc2009
- AbelsonMBTorkildsenGLWilliamsJITime to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single center, prospective, randomized, double masked, placebo controlled, conjunctival allergen challenge assessment in adults and childrenClin Ther2009311908192119843481
- WilliamsJISchooleyGLGowJAMcNamaraTRBepreve 1.5% provides clinically meaningful reduction in allergen-induced ocular itching for subjects in an analysis of two phase 3 conjunctival allergen challenge (CAC) clinical trials. [AAAI abstract 151]J Allergy Clin Immunol20101252 Suppl 1AB38
- ClarkJCWilliamsJIGowJABepotastine besilate ophthalmic solution 1.5% rapidly eliminates ocular itching in more severely allergic subjects in the conjunctival allergen challenge model of allergic conjunctivitisPoster presented at the Eastern Allergy ConferencePalm Beach, FLMay 6–9, 2010
- Pataday™. [Package insert]Fort Worth, TXLaboratories Inc2010
- BerdyGJSpanglerDLBenschGA comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge modelClin Ther20002282683310945509
- AbelsonMBGreinerJVComparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge modelCurr Med Res Opin2004201953195815701212
- HashiguchiKTangHFujitaTSuematsuKGotohMOkuboKBepotastine besilate tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber)Expert Opin Pharmacother20091052352919216705
- Patanase® Nasal Spray [Prescribing information]Fort Worth, TXAlcon Laboratories Inc2008
- SpearsKMcKeeEEdmonsonWAnti-allergy drop comfort and costOptometry201182386
- ArtalMNLunaJDDiscepolaMA forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%Acta Ophthalmol Scand Suppl2000230646511057355
- EpsteinABvan HovenPTKaufmanACarrWWManagement of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studiesClin Ophthalmol2009332933619668586
- ReginsterJYRabendaVNeuprezAAdherence, patient preference and dosing frequency: understanding the relationshipBone200638S2S616520104